RSS   Newsletter   Contact   Advertise with us

MYOS names Joseph DosSantos CFO

Staff writer | Cedar Knolls, NJ, USA | May 20, 2014
MYOSMay 20, 2014, Cedar Knolls, NJ, USA - MYOS Corporation, a company focused on the discovery, development and commercialization of products that improve human muscle health and performance, announced the appointment of Joseph C. DosSantos, as CFO.
Mr. DosSantos is an accomplished finance and accounting executive with nearly twenty-five years of senior-level experience in building and managing global finance teams, including over a decade in the pharmaceutical industry. Additionally, Mr. DosSantos has participated in capital raising initiatives on behalf of private and public companies.

Mr. DosSantos joins MYOS from Actavis plc, a New York Stock Exchange listed global specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products, where he served as Executive Director, Finance Operations.

Previously, he served as Vice President, Corporate Controller, of Alvogen, a multi-national, privately-owned pharmaceutical company focused on developing, manufacturing, and distributing generic, over-the-counter and biosimilar pharmaceutical products.

Mr. DosSantos has also served as Senior Director, Assistant Corporate Controller at Celgene Corporation, a NASDAQ-listed global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases.

Additionally he has held positions of increasing responsibilities at Cytec Industries and National Starch & Chemical, two multi-national chemical companies.

Mr. DosSantos is a licensed certified public accountant in New Jersey, graduated from Kean University in 1991 with a B.S. in Accountancy and holds an M.B.A. in Finance from Seton Hall University.

Carl DeFreitas will assume the role of Vice President and Corporate Controller.